
Roman Emperor Caligula had an unexpected interest in medicinal plants, historians find
A new study co-authored by Trevor Luke, a professor of classics at Florida State University, centers on an overlooked anecdote by the Roman historian Suetonius involving Caligula and an ailing senator.
Advertisement
The account indicates that the unnamed Roman senator traveled to the Greek town of Antikyra to be treated with the medicinal plant hellebore, which is now considered poisonous. Though the treatments were not necessarily expensive, reaching Antikyra – and staying there – was.
When the senator asked Caligula if he could stay longer, the much-hated leader had him executed — claiming it was 'necessary, for one whom hellebore had not benefited in all that time.'
5 A new study centers on an overlooked anecdote by the Roman historian Suetonius involving Caligula and an ailing senator.
Alfredo Dagli Orti/Shutterstock
The story indicates that Caligula had some knowledge of medicinal plants – a prospect that intrigued Luke, who spoke with Fox News Digital about his research.
Advertisement
When asked if he was surprised by Caligula's interest in plants, Luke replied, 'Yes and no.'
'I knew Caligula had a reputation for being a prolific poisoner, and such a murderer might be expected to possess a detailed knowledge of the properties of toxic plants,' Luke said.
'That said, murder by poisoning was a common theme in ancient literature about bad rulers and their families,' the historian added.
5 The story indicates that Caligula had some knowledge of medicinal plants – a prospect that intrigued Luke.
Ivan – stock.adobe.com
Advertisement
Luke said that, as he dug into more ancient sources and archaeological studies, he noticed mounting evidence of Caligula's interest in medicinal plants – which he wasn't expecting.
Alexander the Great, Attalus III of Pergamon and Mithradates VI Eupator are other ancient leaders who took an interest in plants, Luke said — with Caligula possibly consulting pharmacological a text attributed to Mithradates.
Study co-author Andrew Koh noted that Antikyra was similar to the modern-day Mayo Clinic, drawing faraway people to the port by offering treatments for relentless illnesses.
5 Luke said that, as he dug into more ancient sources and archaeological studies, he noticed mounting evidence of Caligula's interest in medicinal plants.
Getty Images
Advertisement
'In other words, Antikyra may be the first known destination in Greece for Roman medical tourists,' Luke said.
'When we think of a brand-name destination for innovative and effective medical treatments, the name Mayo Clinic immediately springs to mind, just as the name Antikyra did in the minds of ancient inhabitants of the Roman Empire for similar reasons.'
He notes that Antikyra healers added a locally grown plant called sesamoides to their hellebore recipes, making them the safest and most effective purgative treatments at the time.
So, was the Roman emperor a 'plant nerd' in the modern sense?
5 Alexander the Great, Attalus III of Pergamon and Mithradates VI Eupator are other ancient leaders who took an interest in plants.
Estelle R – stock.adobe.com
Luke told Fox News Digital that he doesn't mind that label, but added that Caligula's interest in the healing and harming power of plants wasn't just a hobby.
'At the same time, any concern he had regarding assassination by poison was justifiable in the circumstances,' Luke said, pointing to the suspicious deaths of several family members, including his father-in-law Germanicus and brother-in-law Lepidus.
The classicist added, '[Caligula's] family members took up the study of poisons and their antidotes … It seems to me that the motive of self-defense behind Caligula's study of plants is different from just being a nerd.'
Advertisement
5 Antikyra healers added sesamoides to their hellebore recipes, making them the safest and most effective purgative treatments at the time.
Getty Images
Above all, Luke suggested that modern readers should read ancient sources like Suetonius with a critical eye, noting that his stories about Caligula were 'skillfully organized … in such a way that they shocked readers.'
'Shock does not lead to a clear perception of the facts,' Luke said.
'When I pursue the facts behind some of the most outrageous stories about Caligula, I often find Suetonius has deftly distorted what likely happened.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Engadget
a day ago
- Engadget
Google DeepMind's Aeneas model can restore fragmented Latin text
At its best, AI is a tool, not an end result. It allows people to do their jobs better, rather than sending them or their colleagues to the breadline. In an example of "the good kind," Google DeepMind has created an AI model that restores and contextualizes ancient inscriptions. Aeneas (no, it's not pronounced like that ) is named after the hero in Roman mythology. Best of all, the tool is open-source and free to use. Ancient Romans left behind a plethora of inscriptions. But these texts are often fragmented, weathered or defaced. Rebuilding the missing pieces is a grueling task that requires contextual cues. An algorithm that can pore over a dataset of those cues can come in handy. Aeneas speeds up one of historians' most difficult tasks: identifying "parallels." In this setting, that means finding similar texts arranged by wording, syntax or region. DeepMind says the model reasons across thousands of Latin inscriptions. It can fetch parallels in seconds before passing the baton back to historians. DeepMind says it turns each text into a historical fingerprint of sorts. "Aeneas identifies deep connections that can help historians situate inscriptions within their broader historical context," the Google subsidiary wrote. One of Aeneas' most impressive tricks is restoring textual gaps of unknown length. (Think of it as filling out a crossword puzzle where you don't know how many letters are in each clue.) The tool is also multimodal, meaning it can analyze both textual and visual input. DeepMind says it's the first model that can use that multi-pronged method to figure out where a text came from. DeepMind says Aeneas is designed to be a collaborative ally within historians' existing workflows. It's best used to offer "interpretable suggestions" that serve as a starting point for researchers. "Aeneas' parallels completely changed my perception of the inscription," an unnamed historian who tested the model wrote. "It noticed details that made all the difference for restoring and chronologically attributing the text." Alongside the release of Aeneas for Latin text, DeepMind also upgraded Ithaca. (That's its model for Ancient Greek text.) Ithaca is now powered by Aeneas, receiving its contextual and restorative superpowers. Researchers can take Aeneas for a spin at DeepMind's "Predicting the Past" website. It also open-sourced the model's code and dataset.
Yahoo
a day ago
- Yahoo
Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test
Company Launches New Website, Scales Test Access Alongside Mayo Clinic, & Looks to Expand International Presence SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, has announced several strategic growth initiatives to broaden access to its SAAmplify-ɑSYN test. These initiatives include a comprehensive website refresh, expanded test availability via Mayo Clinic's network of hospitals and clinical sites, and ongoing preparations for international expansion. As part of its continuing growth and commitment to advancing early and accurate diagnosis, Amprion will showcase its latest developments and momentum at the Alzheimer's Association International Conference (AAIC), July 27-31, 2025, in Toronto, Canada. Attendees can connect with the Amprion team at booth #616. Following its recent collaboration with Mayo Clinic Laboratories, Amprion launched a newly redesigned website to meet the growing demand for its SAAmplify-ɑSYN test, which aids in the diagnosis of synucleinopathies. The breakthrough test can detect the presence of aggregates of alpha-synuclein protein, the underlying pathology of Parkinson's disease (PD), Lewy body dementia (LBD), multiple system atrophy (MSA), and Alzheimer's disease with Lewy bodies (AD + DLB), in cerebrospinal fluid. Launched earlier this month, the updated website is designed to provide patients, clinicians, and industry leaders with streamlined access to Amprion's latest research, information, and more. "As awareness and demand for our SAAmplify-ɑSYN test grow, we're working to ensure clinicians, researchers, and patients have better access to the tools and information they need," said Dr. Russ Lebovitz, CEO and co-founder of Amprion. "Our refreshed website and expanding partnerships are steps toward that goal, and we look forward to connecting with the global neuroscience community at AAIC." Due to this surge in awareness, Amprion is actively exploring international expansion opportunities, with plans to bring its test to European and global markets. Initial announcements regarding country-specific launch strategies are expected in Q4 2025. For more information or to schedule a meeting with Amprion at AAIC 2025, please visit About SAAmplify-ɑSYN (formerly SYNTap®) Amprion's SAAmplify-ɑSYN test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer's disease (AD) with Lewy body co-pathology. The U.S. Food and Drug Administration (FDA) granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in the diagnosis of PD. The test became commercially available in the US in 2021. About Amprion Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion's intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-ɑSYN (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease, Lewy body dementia, and Alzheimer's disease with Lewy body co-pathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at or find us on LinkedIn. View source version on Contacts Media Contacts Liz RobinsonCG Lifelrobinson@ Karen SharmaCG Lifeksharma@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
a day ago
- Business Wire
Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test
SAN DIEGO--(BUSINESS WIRE)-- Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, has announced several strategic growth initiatives to broaden access to its SAAmplify-ɑSYN test. These initiatives include a comprehensive website refresh, expanded test availability via Mayo Clinic's network of hospitals and clinical sites, and ongoing preparations for international expansion. As part of its continuing growth and commitment to advancing early and accurate diagnosis, Amprion will showcase its latest developments and momentum at the Alzheimer's Association International Conference (AAIC), July 27-31, 2025, in Toronto, Canada. Attendees can connect with the Amprion team at booth #616. Following its recent collaboration with Mayo Clinic Laboratories, Amprion launched a newly redesigned website to meet the growing demand for its SAAmplify-ɑSYN test, which aids in the diagnosis of synucleinopathies. The breakthrough test can detect the presence of aggregates of alpha-synuclein protein, the underlying pathology of Parkinson's disease (PD), Lewy body dementia (LBD), multiple system atrophy (MSA), and Alzheimer's disease with Lewy bodies (AD + DLB), in cerebrospinal fluid. Launched earlier this month, the updated website is designed to provide patients, clinicians, and industry leaders with streamlined access to Amprion's latest research, information, and more. 'As awareness and demand for our SAAmplify-ɑSYN test grow, we're working to ensure clinicians, researchers, and patients have better access to the tools and information they need,' said Dr. Russ Lebovitz, CEO and co-founder of Amprion. 'Our refreshed website and expanding partnerships are steps toward that goal, and we look forward to connecting with the global neuroscience community at AAIC.' Due to this surge in awareness, Amprion is actively exploring international expansion opportunities, with plans to bring its test to European and global markets. Initial announcements regarding country-specific launch strategies are expected in Q4 2025. For more information or to schedule a meeting with Amprion at AAIC 2025, please visit About SAAmplify-ɑSYN (formerly SYNTap®) Amprion's SAAmplify-ɑSYN test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer's disease (AD) with Lewy body co-pathology. The U.S. Food and Drug Administration (FDA) granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in the diagnosis of PD. The test became commercially available in the US in 2021. About Amprion Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion's intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-ɑSYN (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease, Lewy body dementia, and Alzheimer's disease with Lewy body co-pathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at or find us on LinkedIn.